CY1125148T1 - Θεραπεια συνδυασμου με αντι-cd19 αντισωμα και αναλογο πουρινης - Google Patents

Θεραπεια συνδυασμου με αντι-cd19 αντισωμα και αναλογο πουρινης

Info

Publication number
CY1125148T1
CY1125148T1 CY20221100284T CY221100284T CY1125148T1 CY 1125148 T1 CY1125148 T1 CY 1125148T1 CY 20221100284 T CY20221100284 T CY 20221100284T CY 221100284 T CY221100284 T CY 221100284T CY 1125148 T1 CY1125148 T1 CY 1125148T1
Authority
CY
Cyprus
Prior art keywords
antibody
pourine
analogue
combination therapy
hodgkin
Prior art date
Application number
CY20221100284T
Other languages
Greek (el)
English (en)
Inventor
Jutta AMERSDORFFER
Stefan Steidl
Mark Winderlich
Susanne KROHN
Lisa Rojkjaer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of CY1125148T1 publication Critical patent/CY1125148T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CY20221100284T 2011-08-16 2022-04-14 Θεραπεια συνδυασμου με αντι-cd19 αντισωμα και αναλογο πουρινης CY1125148T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161523862P 2011-08-16 2011-08-16
EP11177660 2011-08-16

Publications (1)

Publication Number Publication Date
CY1125148T1 true CY1125148T1 (el) 2024-12-13

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100284T CY1125148T1 (el) 2011-08-16 2022-04-14 Θεραπεια συνδυασμου με αντι-cd19 αντισωμα και αναλογο πουρινης

Country Status (25)

Country Link
US (3) US20140227277A1 (OSRAM)
EP (2) EP2744826B1 (OSRAM)
JP (1) JP6114273B2 (OSRAM)
KR (3) KR102117202B1 (OSRAM)
CN (1) CN103703027B (OSRAM)
AU (1) AU2012296905B2 (OSRAM)
BR (1) BR112013033916B1 (OSRAM)
CA (1) CA2841738C (OSRAM)
CY (1) CY1125148T1 (OSRAM)
DK (1) DK2744826T3 (OSRAM)
ES (1) ES2909720T3 (OSRAM)
HR (1) HRP20220224T1 (OSRAM)
HU (1) HUE058855T2 (OSRAM)
IL (1) IL230295B (OSRAM)
LT (1) LT2744826T (OSRAM)
MX (1) MX353589B (OSRAM)
PL (1) PL2744826T3 (OSRAM)
PT (1) PT2744826T (OSRAM)
RS (1) RS63121B1 (OSRAM)
RU (1) RU2664462C9 (OSRAM)
SG (1) SG10201606788VA (OSRAM)
SI (1) SI2744826T1 (OSRAM)
SM (1) SMT202200160T1 (OSRAM)
WO (1) WO2013024095A1 (OSRAM)
ZA (1) ZA201401835B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
US20170137516A1 (en) * 2014-06-16 2017-05-18 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
US10617691B2 (en) * 2015-05-26 2020-04-14 Morphosys Ag Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
DK3337506T3 (da) 2015-08-21 2021-09-06 Morphosys Ag Kombinationer og anvendelser deraf
SMT202100291T1 (it) * 2016-05-30 2021-07-12 Morphosys Ag Metodi per prevedere il beneficio terapeutico di una terapia anti-cd19 in pazienti
SG10202104036QA (en) * 2016-10-28 2021-05-28 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
CA3062400A1 (en) 2017-05-31 2018-12-06 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
CN110945028B (zh) 2017-07-10 2023-09-08 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
TW202334231A (zh) * 2021-12-22 2023-09-01 德商莫菲西斯公司 抗cd19抗體療法的治療範例
WO2025012080A1 (en) 2023-07-13 2025-01-16 Christian-Albrechts-Universität Zu Kiel Humanized anti-cd7 antibody

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11852A (en) 1854-10-31 Abraham bassford
US106A (en) 1915-08-24 Specipication
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
JP2002522511A (ja) * 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
WO2000074718A1 (en) 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
CN1592645A (zh) 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
ES2365046T3 (es) * 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
ME01786B (me) * 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
CN103694349A (zh) 2006-09-08 2014-04-02 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
EP3392273A1 (en) 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
AR077867A1 (es) * 2009-08-14 2011-09-28 Roche Glycart Ag Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
WO2011057222A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Also Published As

Publication number Publication date
EP4083071A3 (en) 2023-02-22
EP2744826A1 (en) 2014-06-25
LT2744826T (lt) 2022-04-25
KR20200060779A (ko) 2020-06-01
SMT202200160T1 (it) 2022-05-12
KR20140071368A (ko) 2014-06-11
ZA201401835B (en) 2015-06-24
BR112013033916B1 (pt) 2022-11-16
RU2664462C2 (ru) 2018-08-17
DK2744826T3 (da) 2022-03-28
IL230295B (en) 2018-03-29
AU2012296905B2 (en) 2017-01-05
EP2744826B1 (en) 2022-02-09
RS63121B1 (sr) 2022-05-31
PL2744826T3 (pl) 2022-05-30
KR102117202B1 (ko) 2020-06-01
HUE058855T2 (hu) 2022-09-28
CA2841738A1 (en) 2013-02-21
US20140227277A1 (en) 2014-08-14
US20200352975A1 (en) 2020-11-12
CN103703027B (zh) 2018-01-12
PT2744826T (pt) 2022-05-19
HRP20220224T1 (hr) 2022-04-29
ES2909720T3 (es) 2022-05-10
MX353589B (es) 2018-01-19
US20240424012A1 (en) 2024-12-26
CA2841738C (en) 2022-12-06
MX2013014935A (es) 2014-07-09
SG10201606788VA (en) 2016-09-29
WO2013024095A1 (en) 2013-02-21
EP4083071A2 (en) 2022-11-02
RU2014103490A (ru) 2015-09-27
SI2744826T1 (sl) 2022-05-31
BR112013033916A2 (pt) 2017-11-28
JP2014525925A (ja) 2014-10-02
RU2664462C9 (ru) 2018-09-28
NZ617771A (en) 2016-01-29
CN103703027A (zh) 2014-04-02
JP6114273B2 (ja) 2017-04-12
KR20190094478A (ko) 2019-08-13

Similar Documents

Publication Publication Date Title
CY1125148T1 (el) Θεραπεια συνδυασμου με αντι-cd19 αντισωμα και αναλογο πουρινης
CY1125122T1 (el) Θεραπεια συνδυασμου me anti-cd19 αντισωμα και μουσταρδα αζωτου
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
CY1122298T1 (el) Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CY1124648T1 (el) Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου
CY1124706T1 (el) Συνδυασμοι και χρησεις αυτων
CY1119840T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
BR112017005314A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
HUE065848T2 (hu) Kombinációs terápia a claudin 18.2 elleni antitestekkel a rák kezelésére
CY1122185T1 (el) Ιατρικη χρηση ενωσεων αρτεμισινινης και αγωνιστων γεφυρινης
BR112014016062B8 (pt) método para fabricação de um artigo limpável, artigo limpável e método para utilizar um artigo limpável
EP3054954A4 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
BR112015027399A2 (pt) ANTICORPOS ANTI-IGF-1R COM LIGAÇÃO DE FcRn ABOLIDA E SEU USO NO TRATAMENTO DE ENFERMIDADES VASCULARES OCULARES
CY1118968T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
EP2703710A4 (en) POLYCARBONATE RESIN COMPOSITION FOR A TRANSPARENT BODY AND TRANSPARENT BODY AND SURFACE LIGHT SOURCE